Indian pharmaceutical stocks showed gains in morning trade on January 22, 2026, amid a broader market uptrend. The BSE Sensex rose over 500 points to around 82,418, while the Nifty 50 climbed above 25,330, reflecting positive sentiment across indices.
Many pharma scrips traded higher on the BSE and NSE as of approximately 9:54 AM IST. Notable performers included:
- Dr. Reddy’s Laboratories, up around 5% (BSE: 1,213.50, +5.02%; NSE: 1,212.30, +4.76%), following Q3 FY26 results.
- Granules India, up 4.55% on BSE and 4.33% on NSE.
- Pfizer, up 3.96% on BSE and 3.80% on NSE.
- Strides Pharma Science, up nearly 4% on both exchanges.
- Morepen Labs, up 3.90% on BSE and 3.73% on NSE.
- SMS Pharma, up around 3.89%.
- Solara Active Pharma Sciences, up 4.90% on BSE and 4.74% on NSE.
Other stocks with gains of 2-3% included BioCon, Jubilant Pharmova, Laurus Labs, Mankind Pharma, Marksans Pharma, Panacea Biotech, Piramal Pharma, Sai Life Sciences, Sequent Scientific, Shilpa Medicare, and Wockhardt.
The list also featured moderate rises in major names such as Sun Pharma (around 1.95-1.98%), Cipla (0.83-0.90%), Divi’s Laboratories (1.26-1.29%), Alkem Laboratories, Aurobindo Pharma, Glenmark Pharma, Lupin, and Torrent Pharma.
A few stocks traded lower, including Dr. Lal Pathlabs (-1.06% to -1.14%), Max Healthcare Institute, Metropolis Healthcare, and Vijaya Diagnostic. Jubilant Industries saw a decline of over 4%.
This data reflects snapshot prices and percentage changes as of around 9:54 AM IST on January 22, 2026.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
